Screener
BioMarin Pharmaceuticals BMRN Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable and accrued operating expenses | $406,977 | $312,768 |
| Accrued rebates payable | 243,526 | 166,925 |
| Accrued compensation expense | 220,506 | 219,422 |
| Accrued Interest | 47,129 | 907 |
| Foreign currency exchange forward contracts | 33,525 | 31,007 |
| Lease liability | 16,058 | 8,685 |
| Accrued royalties payable | 15,502 | 7,968 |
| Accrued income taxes | 9,137 | 3,667 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's accrued manufacturing costs?
- BioMarin Pharmaceuticals (BMRN) reported accrued manufacturing costs of $220.51M in Q2 2026.
- How has BioMarin Pharmaceuticals's accrued manufacturing costs changed year-over-year?
- BioMarin Pharmaceuticals's accrued manufacturing costs increased by 84.7% year-over-year, from $119.41M to $220.51M.
- What is the long-term trend for BioMarin Pharmaceuticals's accrued manufacturing costs?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accrued manufacturing costs has grown at a 5.9% compound annual growth rate (CAGR), from $165.02M to $219.42M.
- What does accrued manufacturing costs mean?
- Accrued liabilities related to manufacturing and production activities.
Ask your AI about BioMarin Pharmaceuticals's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude